Effects of hypoxia-inducible factor-1α and hypoxia-inducible factor-2α overexpression on hepatocellular carcinoma survival: A systematic review with meta-analysis
- PMID: 33393670
- DOI: 10.1111/jgh.15395
Effects of hypoxia-inducible factor-1α and hypoxia-inducible factor-2α overexpression on hepatocellular carcinoma survival: A systematic review with meta-analysis
Abstract
Background and aim: The role of hypoxia-inducible factor-1α (HIF-1α) and hypoxia-inducible factor-2α (HIF-2α) has been implicated in the clinical prognosis of hepatocellular carcinoma (HCC), but the results remain controversial. We aim to investigate the association of HIF-1α and HIF-2α overexpression with the prognosis and clinicopathological features of HCC.
Methods: A systematic search was conducted in PubMed, Embase, Scopus, Web of Science, and Cochrane Library until June 20, 2020. Meta-analysis was conducted to generate combined HRs with 95% confidence intervals (CI) for overall survival (OS) and disease-free survival (DFS). Odds ratios (ORs) with 95% CI were also derived by fixed or random effect model.
Results: Twenty-two studies involving 3238 patients were included. Combined data suggested that overexpression of HIF-1α in HCC was not only correlated with poorer OS [HR = 1.75 (95% CI: 1.53-2.00)] and DFS [HR = 1.64 (95% CI: 1.34-2.00)] but was also positively associated with vascular invasion [OR = 1.83 (95% CI: 1.36-2.48)], tumor size [OR = 1.36 (95% CI: 1.12-1.66)], and tumor number [1.74 (95% CI: 1.34-2.25)]. In contrast, HIF-2α overexpression was not associated with the prognosis and clinicopathological features of HCC.
Conclusion: Our data provided compelling evidence of a worse prognosis of HCC in HIF-1α overexpression patients but not HIF-2α overexpression ones.
Keywords: HIF-1α; HIF-2α; hepatocellular carcinoma; meta-analysis; prognosis.
© 2021 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
Similar articles
-
Prognostic and clinicopathological significance of hypoxia-inducible factors 1α and 2α in hepatocellular carcinoma: a systematic review with meta-analysis.Ther Adv Med Oncol. 2021 Feb 7;13:1758835920987071. doi: 10.1177/1758835920987071. eCollection 2021. Ther Adv Med Oncol. 2021. PMID: 33613697 Free PMC article.
-
Prognostic significance of HIF-1α expression in hepatocellular carcinoma: a meta-analysis.PLoS One. 2013 Jun 14;8(6):e65753. doi: 10.1371/journal.pone.0065753. Print 2013. PLoS One. 2013. PMID: 23799043 Free PMC article.
-
Mild chronic hypoxia-induced HIF-2α interacts with c-MYC through competition with HIF-1α to induce hepatocellular carcinoma cell proliferation.Cell Oncol (Dordr). 2021 Oct;44(5):1151-1166. doi: 10.1007/s13402-021-00625-w. Epub 2021 Aug 2. Cell Oncol (Dordr). 2021. PMID: 34339013
-
Clinicopathological and prognostic value of hypoxia-inducible factor-1α in patients with bone tumor: a systematic review and meta-analysis.J Orthop Surg Res. 2019 Feb 19;14(1):56. doi: 10.1186/s13018-019-1101-5. J Orthop Surg Res. 2019. PMID: 30782196 Free PMC article.
-
Clinicopathological and prognostic value of hypoxia-inducible factor-1α in breast cancer: a meta-analysis including 5177 patients.Clin Transl Oncol. 2020 Oct;22(10):1892-1906. doi: 10.1007/s12094-020-02332-8. Epub 2020 Mar 12. Clin Transl Oncol. 2020. PMID: 32166713 Review.
Cited by
-
Identification of BHLHE40 expression in peripheral blood mononuclear cells as a novel biomarker for diagnosis and prognosis of hepatocellular carcinoma.Sci Rep. 2021 May 27;11(1):11201. doi: 10.1038/s41598-021-90515-w. Sci Rep. 2021. PMID: 34045534 Free PMC article.
-
Hypoxia-inducible factor-1α: A critical target for inhibiting the metastasis of hepatocellular carcinoma.Oncol Lett. 2022 Jun 28;24(2):284. doi: 10.3892/ol.2022.13404. eCollection 2022 Aug. Oncol Lett. 2022. PMID: 35814827 Free PMC article. Review.
-
Metabolism-Associated Epigenetic and Immunoepigenetic Reprogramming in Liver Cancer.Cancers (Basel). 2021 Oct 19;13(20):5250. doi: 10.3390/cancers13205250. Cancers (Basel). 2021. PMID: 34680398 Free PMC article. Review.
-
Carvacrol potentiates immunity and sorafenib anti-cancer efficacy by targeting HIF-1α/STAT3/ FGL1 pathway: in silico and in vivo study.Naunyn Schmiedebergs Arch Pharmacol. 2025 Apr;398(4):4335-4353. doi: 10.1007/s00210-024-03530-9. Epub 2024 Oct 28. Naunyn Schmiedebergs Arch Pharmacol. 2025. PMID: 39466438 Free PMC article.
-
Dietary Fat Composition Affects Hepatic Angiogenesis and Lymphangiogenesis in Hepatitis C Virus Core Gene Transgenic Mice.Liver Cancer. 2022 Sep 16;12(1):57-71. doi: 10.1159/000525546. eCollection 2023 Feb. Liver Cancer. 2022. PMID: 36872924 Free PMC article.
References
-
- Forner A, Reig M, Bruix J. Hepatocellular carcinoma. The Lancet. 2018; 391: 1301-1314.
-
- Li T, Wang SK, Zhou J et al. Positive HBcAb is associated with higher risk of early recurrence and poorer survival after curative. Liver Int. 2016; 36: 284-292.
-
- Brown ZJ, Greten TF, Heinrich B. Adjuvant treatment of hepatocellular carcinoma: prospect of immunotherapy. Hepatology 2019; 70: 1437-1442.
-
- Li T, Qin LX, Gong X et al. Hepatitis B virus surface antigen-negative and hepatitis C virus antibody-negative hepatocellular carcinoma: clinical characteristics, outcome, and risk factors for early and late intrahepatic recurrence after resection. Cancer 2013; 119: 126-135.
-
- Dong ZR, Sun D, Yang YF et al. TMPRSS4 drives angiogenesis in hepatocellular carcinoma by promoting HB-EGF expression and proteolytic cleavage. Hepatology 2020; 72: 923-939.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical